Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-sensitive Relapsed Epithelial Ovarian Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT01869400
What this trial is testing

An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer

Who this might be right for
Recurrent Ovarian Cancer
PharmaMar, Spain 83
Testing effectiveness (Phase 2)Study completedNCT03759587
What this trial is testing

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Takeda 19
Large-scale testing (Phase 3)Study completedNCT03402841
What this trial is testing

Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients

Who this might be right for
Non-Germline BRCA Mutated Ovarian Cancer
AstraZeneca 279
Testing effectiveness (Phase 2)Study completedNCT00217568
What this trial is testing

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Who this might be right for
Ovarian CancerPeritoneal Cavity Cancer
Fred Hutchinson Cancer Center
Not applicableUnknownNCT04369352
What this trial is testing

Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria

Who this might be right for
Recurrent Ovarian Carcinoma
Medical University Innsbruck 150
Large-scale testing (Phase 3)UnknownNCT03705156
What this trial is testing

Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient

Who this might be right for
Platinum-sensitive Relapsed Ovarian Cancer
Zai Lab (Shanghai) Co., Ltd. 265
Testing effectiveness (Phase 2)Ended earlyNCT04826198
What this trial is testing

Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months

Who this might be right for
Ovarian Cancer
Gustave Roussy, Cancer Campus, Grand Paris 13
Large-scale testing (Phase 3)UnknownNCT00532194
What this trial is testing

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Who this might be right for
Ovarian Cancer
Medical Research Council 486
Testing effectiveness (Phase 2)Study completedNCT00090610
What this trial is testing

Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer

Who this might be right for
Ovarian Cancer
Duke University 150
Not applicableNo Longer AvailableNCT03063710
What this trial is testing

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

Who this might be right for
PSR Ovarian Cancer With a BRCA Mutation
AstraZeneca
Testing effectiveness (Phase 2)Study completedNCT02107950
What this trial is testing

Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma

Who this might be right for
Ovarian NeoplasmsOvarian Cancer (OvCa)Ovarian Epithelial Cancer
SOTIO a.s. 71
Testing effectiveness (Phase 2)Ended earlyNCT00247988
What this trial is testing

Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers

Who this might be right for
Platinum Sensitive Relapsed Ovarian Cancer
University of Saskatchewan 38
Testing effectiveness (Phase 2)Study completedNCT00753545
What this trial is testing

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Who this might be right for
Ovarian Cancer
AstraZeneca 265
Testing effectiveness (Phase 2)Study completedNCT01705158
What this trial is testing

Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum

Who this might be right for
Ovarian Cancer
ARCAGY/ GINECO GROUP 87
Not applicableStudy completedNCT05512676
What this trial is testing

Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum

Who this might be right for
Ovarian NeoplasmChemotherapeutic ToxicityChemotherapy Effect+2 more
Oslo University Hospital 40
Early research (Phase 1)Study completedNCT01314105
What this trial is testing

BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer

Who this might be right for
Ovarian NeoplasmsPeritoneal Neoplasms
Boehringer Ingelheim 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06081595
What this trial is testing

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Who this might be right for
Relapsed Ovarian Cancer
Jin Li 54
Testing effectiveness (Phase 2)Study completedNCT01472783
What this trial is testing

Veliparib Monotherapy for Relapsed Ovarian Cancer With BRCA Mutation

Who this might be right for
Recurrent, Epithelial Ovarian Cancer
Vejle Hospital 49
Testing effectiveness (Phase 2)Study completedNCT01891344
What this trial is testing

Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

Who this might be right for
Ovarian CancerEpithelial Ovarian CancerFallopian Tube Cancer+1 more
pharmaand GmbH 491
Large-scale testing (Phase 3)Ended earlyNCT00849667
What this trial is testing

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Who this might be right for
Ovarian Cancer
Morphotek 1,100
Next Page